Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"

Stavros Apostolakis; Deirdre A Lane; Amitava Banerjee

doi:10.1161/CIRCULATIONAHA.112.000708

Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"

Stavros Apostolakis, Deirdre A Lane, Amitava Banerjee

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Original language	English
Pages (from-to)	e171
Journal	Circulation
Volume	128
Issue number	11
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.112.000708
Publication status	Published - 10 Sept 2013

Keywords

Atrial Fibrillation
Embolism
Factor Xa
Female
Humans
Male
Morpholines
Stroke
Thiophenes
Vitamin K

Access to Document

10.1161/CIRCULATIONAHA.112.000708

Cite this

Apostolakis, S., Lane, D. A., & Banerjee, A. (2013). Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation, 128(11), e171. https://doi.org/10.1161/CIRCULATIONAHA.112.000708

Apostolakis, Stavros ; Lane, Deirdre A ; Banerjee, Amitava. / Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation : validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". In: Circulation. 2013 ; Vol. 128, No. 11. pp. e171.

@article{4ab1f193ba524615b11ec5ee0a3135cd,

title = "Letter by Apostolakis et al regarding article, {"}renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts{"}",

keywords = "Atrial Fibrillation, Embolism, Factor Xa, Female, Humans, Male, Morpholines, Stroke, Thiophenes, Vitamin K",

author = "Stavros Apostolakis and Lane, {Deirdre A} and Amitava Banerjee",

year = "2013",

month = sep,

day = "10",

doi = "10.1161/CIRCULATIONAHA.112.000708",

language = "English",

volume = "128",

pages = "e171",

journal = "Circulation",

issn = "0009-7322",

publisher = "American Heart Association",

number = "11",

}

Apostolakis, S, Lane, DA & Banerjee, A 2013, 'Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"', Circulation, vol. 128, no. 11, pp. e171. https://doi.org/10.1161/CIRCULATIONAHA.112.000708

Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". / Apostolakis, Stavros; Lane, Deirdre A; Banerjee, Amitava.
In: Circulation, Vol. 128, No. 11, 10.09.2013, p. e171.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

T2 - validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"

AU - Apostolakis, Stavros

AU - Lane, Deirdre A

AU - Banerjee, Amitava

PY - 2013/9/10

Y1 - 2013/9/10

KW - Atrial Fibrillation

KW - Embolism

KW - Factor Xa

KW - Female

KW - Humans

KW - Male

KW - Morpholines

KW - Stroke

KW - Thiophenes

KW - Vitamin K

U2 - 10.1161/CIRCULATIONAHA.112.000708

DO - 10.1161/CIRCULATIONAHA.112.000708

M3 - Article

C2 - 24019451

SN - 0009-7322

VL - 128

SP - e171

JO - Circulation

JF - Circulation

IS - 11

ER -

Apostolakis S, Lane DA, Banerjee A. Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sept 10;128(11):e171. doi: 10.1161/CIRCULATIONAHA.112.000708